Finally, while comparisons between IDH1wt and IDH1mut patient tumors and gliomaspheres with disparate genetic backgrounds have been used to establish differences in m6A levels, our mechanistic experiments in which we determine effects of IDH1 mutation expression or treatment with D-2-HG or IDH inhibitor on glioma cells provide some control for genetic background. This evidence concerns the gene IDH1 and central nervous system cancer.